132 related articles for article (PubMed ID: 37313979)
1. Methotrexate Polyglutamates Exposure - Response Modeling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate.
Hebing RCF; Bartelink IH; Gosselt HR; Heil SG; de Rotte MCFJ; de Jong PHP; Nurmohamed MT; de Jonge R; Mathôt RAA
Clin Pharmacol Ther; 2023 Oct; 114(4):893-903. PubMed ID: 37313979
[TBL] [Abstract][Full Text] [Related]
2. Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study.
Musdalita E; Hidayat R; Sumariyono S; Kusumo Wibowo SA; Ariane A; Shatri H; Rengganis I; Antono D
F1000Res; 2022; 11():187. PubMed ID: 35284067
[No Abstract] [Full Text] [Related]
3. Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis.
Pan S; Stamp LK; Duffull SB; Barclay ML; Dalrymple JM; Drake J; Zhang M; Korell J
Clin Pharmacokinet; 2014 Dec; 53(12):1161-70. PubMed ID: 25204405
[TBL] [Abstract][Full Text] [Related]
4. Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis.
den Boer E; de Rotte MC; Pluijm SM; Heil SG; Hazes JM; de Jonge R
J Rheumatol; 2014 Nov; 41(11):2167-78. PubMed ID: 25225283
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial.
Hebing RC; Lin M; Bulatovic Calasan M; Muller IB; Mahmoud S; Heil S; Struys EA; van den Bemt BJ; Twisk JW; Lems W; Nurmohamed MT; Jansen G; de Jonge R
Ann Rheum Dis; 2023 Apr; 82(4):460-467. PubMed ID: 36543526
[TBL] [Abstract][Full Text] [Related]
6. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; Frampton C; James J; Barclay ML
Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
[TBL] [Abstract][Full Text] [Related]
7. A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells.
Korell J; Stamp LK; Barclay ML; Dalrymple JM; Drake J; Zhang M; Duffull SB
Clin Pharmacokinet; 2013 Jun; 52(6):475-85. PubMed ID: 23483363
[TBL] [Abstract][Full Text] [Related]
8. A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate.
Stamp LK; OʼDonnell JL; Frampton C; Drake J; Zhang M; Barclay M; Chapman PT
J Clin Rheumatol; 2019 Oct; 25(7):284-287. PubMed ID: 30001258
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
Dhir V; Singla M; Gupta N; Goyal P; Sagar V; Sharma A; Khanna S; Singh S
Clin Ther; 2014 Jul; 36(7):1005-15. PubMed ID: 24976447
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
Goss SL; Klein CE; Jin Z; Locke CS; Rodila RC; Kupper H; Burmester GR; Awni WM
Clin Ther; 2018 Feb; 40(2):309-319. PubMed ID: 29402521
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.
Dervieux T; Furst D; Lein DO; Capps R; Smith K; Caldwell J; Kremer J
Ann Rheum Dis; 2005 Aug; 64(8):1180-5. PubMed ID: 15677700
[TBL] [Abstract][Full Text] [Related]
12. Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity.
Lee JS; Oh JS; Hong S; Kim YG; Lee CK; Yoo B
Int J Rheum Dis; 2020 Aug; 23(8):1076-1081. PubMed ID: 33021334
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis.
de Rotte MC; den Boer E; de Jong PH; Pluijm SM; Ćalasan MB; Weel AE; Huisman AM; Gerards AH; van Schaeybroeck B; Wulffraat NM; Lindemans J; Hazes JM; de Jonge R
Ann Rheum Dis; 2015 Feb; 74(2):408-14. PubMed ID: 24297383
[TBL] [Abstract][Full Text] [Related]
14. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
[TBL] [Abstract][Full Text] [Related]
15. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing methotrexate and methotrexate polyglutamate in patients with rheumatoid arthritis: a systematic review of population pharmacokinetics.
Methaneethorn J; AlEjielat R; Leelakanok N
Drug Metab Pers Ther; 2022 Sep; 37(3):229-240. PubMed ID: 35218177
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis.
de Rotte MCFJ; Pluijm SMF; de Jong PHP; Bulatović Ćalasan M; Wulffraat NM; Weel AEAM; Lindemans J; Hazes JMW; de Jonge R
PLoS One; 2018; 13(12):e0208534. PubMed ID: 30532219
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; James J; Frampton C; Barclay ML
Arthritis Rheum; 2010 Feb; 62(2):359-68. PubMed ID: 20112376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
